Evidence map›Paper›PMID 33564775›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.

Alena J Markmann, Natasa Giallourou, D Ryan Bhowmik, Yixuan J Hou, Aaron Lerner, David R Martinez, Lakshmanane Premkumar, Heather Root, David van Duin, Sonia Napravnik and 14 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 20 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 2 countries.

Alena J MarkmannDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Natasa GiallourouCentre of Excellence in Biobanking and Biomedical Research, Molecular Medicine Research Center, University of Cyprus, Nicosia, Cyprus.
D Ryan BhowmikDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Yixuan J HouDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Aaron LernerDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
David R MartinezDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Heather RootDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
David van DuinDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Sonia NapravnikDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Stephen D GrahamDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Quique GuerraDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Rajendra RautDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Christos J PetropoulosLabCorp-Monogram Biosciences, South San Francisco, CA 94080.
Terri WrinLabCorp-Monogram Biosciences, South San Francisco, CA 94080.
Caleb CornabyDepartment of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
John SchmitzDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
JoAnn KurucDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Susan WeissDepartment of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Yara ParkDepartment of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Ralph BaricDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
David M MargolisDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
Luther A BarteltDepartment of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA.
University of North Carolina at Chapel Hill · USLabCorp (United States) · USUniversity of Cyprus · CY

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
INFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5M
Defining viral and immune mechanisms of Dengue virus serotype 2 immune evasionF32AI152296 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARTINEZ, DAVID R. · 2020 to 2020
$41k
NCATS NIH HHS UL1 TR001863NCI NIH HHS U54 CA260543NIAID NIH HHS F32 AI152296NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI007151NIAID NIH HHS U01 AI069918
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has now caused over 2 million deaths worldwide and continues to expand. Currently, much is unknown about functionally neutralizing human antibody responses and durability to SARS-CoV-2. Using convalescent sera collected from 101 COVID-19 recovered individuals 21-212 days after symptom onset with forty-eight additional longitudinal samples, we measured functionality and durability of serum antibodies. We also evaluated associations between individual demographic and clinical parameters with functional neutralizing antibody responses to COVID-19. We found robust antibody durability out to six months, as well as significant positive associations with the magnitude of the neutralizing antibody response and male sex. We also show that SARS-CoV-2 convalescent neutralizing antibodies are higher in individuals with cardio-metabolic comorbidities.

Indexed as

AntibodiesImmunologyneutralizing antibodiesSARS-CoV-2

Identifiers

PMID33564775
PMCPMC7872367
OpenAlexW3128724794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.